Please login to the form below
Alecensa
This page shows the latest Alecensa news and features for those working in and with pharma, biotech and healthcare.
Pfizer’s Xalkori follow-up Lorbrena hits the mark in first-line lung cancer
Sales of Xalkori have come under pressure recently as it faces increasing pressure from Roche’s Alecensa (alectinib) and Novartis’ Zykadia (ceritinib), with both therapies having previously bested Pfizer’s ... Although Lorbrena will face extreme
Latest news
-
Roche reports continued growth in Q3, despite biosimilar competition
In Europe, sales were down 1% thanks to the competition from biosimilars for Herception and Rituxan, but there was growth reported in the uptake of Ocrevus, Perjeta, Tecentriq, Alecensa and Hemlibra.
-
Pfizer’s Talzenna cleared for breast cancer in Europe
Alecensa (alectinib), Novartis’ Zykadia (ceritinib), and Takeda’s Alunbrig (brigatinib).
-
Pfizer gets EU nod for Tagrisso rival Vizimpro
Roche’s Alecensa (alectinib), Novartis’ Zykadia (ceritinib), and Takeda’s Alunbrig (brigatinib).
-
Pfizer claims rapid FDA nod for Lorbrena
Lorbrena can also be used in patients who have seen disease progression on Roche’s Alecensa and Novartis’ Zykadia.
-
Ocrevus surge keeps Roche smiling in Q3
However, the performance of Ocrevus and other drugs such as HER2 breast cancer therapy Perjeta (pertuzumab) and lung cancer therapy Alecensa (alectinib) – plus a strong showing in Asia-Pacific markets led
More from news
Approximately 16 fully matching, plus 23 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- Senior Account Director - Med Comms Agency
-
Salary TBC
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
-
SENIOR MEDICAL WRITER
-
Salary TBC
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- First dose of Pfizer/BioNTech vaccine reduces COVID-19 infection risk by 70%
- Communique - Communiqué Awards
- GSK launches late-stage testing of RSV vaccine candidate in older adults
- AZ refutes reports suggesting its COVID-19 vaccine is less effective in the elderly
- FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz
- FDA authorises flexible storage for Pfizer/BioNTech COVID-19 vaccine
- UK introduces Rare Diseases Framework to improve the lives of people with rare diseases
- Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease
- UPDATED: Regeneron’s COVID-19 antibody cocktail shows ‘clear efficacy’
- Merck to acquire Pandion Therapeutics for $1.85bn
- bluebird bio marks Rare Disease Day 2021 with launch of patient testimonial video
PMHub
McCann Health Medical Communications
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....
Latest intelligence
- 4 ways to recruit Alzheimer’s disease patients for your clinical trial
- What key things do you need to remember to reach patients living with Alzheimer’s disease?...
- Integrating competitive intelligence into business development, licensing and M&A strategy
- The advantages of partnering with a competitive intelligence or knowledge management team...
- Reaching patients and HCPs during the pandemic
- COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...
Quick links
Infographics
